Advanced search
1 file | 205.51 KB Add to list

The use of desoxycorticosterone pivalate in dogs with hypoadrenocorticism : a retrospective study of eight cases

Author
Organization
Abstract
In this article, the use of desoxycorticosterone pivalate is retrospectively reviewed in eight dogs with primary hypoadrenocorticism, presented at the Small Animal Department of Ghent University. The results showed that desox corticosterone pivalate provided adequate mineralocorticoid replacement in all cases, also in the dogs that had previously been treated with fludrocortisone acetate. A starting dosage of 1.5 - 2.2 mg/kg SC was used, with a fixed dosing interval of 28 days in most of the cases. Each time, prednisolone was added to the therapy as glucocorticoid supplementation. No side effects related to desoxycorticosterone pivalate therapy were noted and all owners were satisfied with the treatment consisting of desoxycorticosterone pivalate and prednisolone.

Downloads

  • art01 in English 0.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 205.51 KB

Citation

Please use this url to cite or link to this publication:

MLA
Albers, Maai, et al. “The Use of Desoxycorticosterone Pivalate in Dogs with Hypoadrenocorticism : A Retrospective Study of Eight Cases.” VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT, vol. 87, no. 6, 2018, pp. 309–13.
APA
Albers, M., Defauw, P., Mortier, F., & Daminet, S. (2018). The use of desoxycorticosterone pivalate in dogs with hypoadrenocorticism : a retrospective study of eight cases. VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT, 87(6), 309–313.
Chicago author-date
Albers, Maai, Pieter Defauw, Femke Mortier, and Sylvie Daminet. 2018. “The Use of Desoxycorticosterone Pivalate in Dogs with Hypoadrenocorticism : A Retrospective Study of Eight Cases.” VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT 87 (6): 309–13.
Chicago author-date (all authors)
Albers, Maai, Pieter Defauw, Femke Mortier, and Sylvie Daminet. 2018. “The Use of Desoxycorticosterone Pivalate in Dogs with Hypoadrenocorticism : A Retrospective Study of Eight Cases.” VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT 87 (6): 309–313.
Vancouver
1.
Albers M, Defauw P, Mortier F, Daminet S. The use of desoxycorticosterone pivalate in dogs with hypoadrenocorticism : a retrospective study of eight cases. VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT. 2018;87(6):309–13.
IEEE
[1]
M. Albers, P. Defauw, F. Mortier, and S. Daminet, “The use of desoxycorticosterone pivalate in dogs with hypoadrenocorticism : a retrospective study of eight cases,” VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT, vol. 87, no. 6, pp. 309–313, 2018.
@article{8618980,
  abstract     = {{In this article, the use of desoxycorticosterone pivalate is retrospectively reviewed in eight dogs with primary hypoadrenocorticism, presented at the Small Animal Department of Ghent University. The results showed that desox corticosterone pivalate provided adequate mineralocorticoid replacement in all cases, also in the dogs that had previously been treated with fludrocortisone acetate. A starting dosage of 1.5 - 2.2 mg/kg SC was used, with a fixed dosing interval of 28 days in most of the cases. Each time, prednisolone was added to the therapy as glucocorticoid supplementation. No side effects related to desoxycorticosterone pivalate therapy were noted and all owners were satisfied with the treatment consisting of desoxycorticosterone pivalate and prednisolone.}},
  author       = {{Albers, Maai and Defauw, Pieter and Mortier, Femke and Daminet, Sylvie}},
  issn         = {{0303-9021}},
  journal      = {{VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{309--313}},
  title        = {{The use of desoxycorticosterone pivalate in dogs with hypoadrenocorticism : a retrospective study of eight cases}},
  volume       = {{87}},
  year         = {{2018}},
}

Web of Science
Times cited: